<DOC>
	<DOCNO>NCT00127517</DOCNO>
	<brief_summary>The purpose study determine whether patient advanced cancer receive AVR118 solution injection skin achieve improvement quality life . Based study patient AIDS , possible benefit may include improved appetite strength ; weight gain ; improve mood ; decrease fatigue . For first three week , patient receive AVR118 , others receive placebo ( injection expect benefit ) . After three week , patient offer opportunity take injection AVR118 .</brief_summary>
	<brief_title>Palliative Care Study Patients With Advanced Cancer</brief_title>
	<detailed_description>Advanced cancer usually debilitate . There treatment available symptom advance cancer like loss appetite , decreased strength , fatigue , change mood . A Phase II , double blind study compare treatment AVR118 placebo , follow open label phase treat patient AVR118 , enable Sponsor gather data safety efficacy AVR118 patient population . Patients age 18-80 advanced cancer ( exclude central nervous system [ CNS ] cancer ) receive chemotherapy , receive single agent , third line ( beyond ) chemotherapy , may eligible participate .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>· Histologically confirm malignancy ( exclude central nervous system malignancy ) · Not candidate , refuse , curative antineoplastic therapy . · Between age 18 80 . · Symptoms advance cancer ( loss appetite , fatigue , weakness , malaise ) attribute anemia , concomitant illness , obstruction loss organ function . · Karnofsky performance status ³40 % , _ &lt; _ 80 % . · Normal cognition , interpret MiniMental State Score least 20 . · Life expectancy &gt; 4 month . · Decrease weight least 5 % precede 6 month , weight gain recent 30 day · Pretreatment laboratory data within 7 day enrollment ( screen lab do within 3 day Day 1 , need repeat Day 1 ) . ¨ Hemoglobin &gt; 8.5 g/dL , stable dos ( hematocrit stable within 1 gram dose stable one month ) Epogen similar medication . ¨ Absolute neutrophil count ( ANC ) ³1,500/mm^3 . ¨ Platelets ³50,000/mm^3 . ¨ Total bilirubin £1.5 upper limit normal ( ULN ) . ¨ ALT AST £2.5 time ULN , , patient liver metastasis , £5 time ULN . ¨ Creatinine £1.5 mg/dL . ¨ Fasting blood sugar &lt; 1.2 x ULN ¨ Normal T3 , T4 , TSH · Voluntary write informed consent performance studyrelated procedure part normal medical care . · Ability selfadminister subcutaneous medication , assistant administer study medication accord protocol . · Female patient postmenopausal , surgically sterilize , willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . · Male patient agree use acceptable barrier method contraception study . · If antidepressant , dose must stabilize least 60 day · Received immunotherapy , radiation therapy experimental therapy within three week . · Receiving chemotherapy thirdline , single agent therapy ; permit thirdline , single agent dose must stable least one month . · Diabetes require insulin oral hypoglycemic agent . · Mechanical reason unable eat , reasonably expect develop obstruction next eight week · Myocardial infarction within six month enrollment . · Uncontrolled brain metastasis central nervous system disease . · Major surgery within four week enrollment . · Severe allergy milk milk product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Oncology</keyword>
	<keyword>Palliative Care</keyword>
	<keyword>Advanced Cancer</keyword>
	<keyword>Palliative Cancer Care</keyword>
</DOC>